Heterogeneity amongst 5-HT3 receptor subunits: Is this significant?

Current Molecular Medicine

Volumn 11, Issue 1, 2011, Pages 57-68

  Yaakob, N ^a   Malone, D T ^a   Exintaris, B ^a   Irving, H R ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

5 HT3 receptors; Chemotherapy induced emesis; Irritable bowel syndrome; Single nucleotide polymorphisms (SNPs)

Indexed keywords

ONDANSETRON; PROTEIN SUBUNIT; SEROTONIN 3 RECEPTOR; TROPISETRON;

AFFECTIVE PSYCHOSIS; ALCOHOLISM; AUTISM; CELL LINE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFICACY; HUMAN; IRRITABLE COLON; NAUSEA AND VOMITING; PAIN; PHARMACOGENOMICS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ALCOHOLISM; ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; AUTISTIC DISORDER; CENTRAL NERVOUS SYSTEM; HUMANS; IRRITABLE BOWEL SYNDROME; MOOD DISORDERS; NAUSEA; PAIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SUBUNITS; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 79551660848     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411794474392     Document Type: Review

References (132)

1. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
2. 3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310: 101-11.
3. 3E. Mol Pharmacol 2007; 72: 8-17.
4. 3 receptors. Curr Pharm Des 2006; 12: 3615-30.
5. 3 receptors aremembrane ion channels. Nature 1989; 339: 706-9.
6. 3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-7.
7. Yang J. Ion permeation through 5-hydroxytryptamine-gatedchannels in neuroblastoma N 18 cells. J Gen Physiol 1990; 96: 1177-98.
8. Beene DL, Price KL, Lester HA, Dougherty DA, Lummis SCR. Tyrosine residues that control binding and gating in the5-hydroxytryptamine3 receptor revealed by unnatural aminoacid mutagenesis. J Neurosci 2004; 24: 9097-104.
9. 3 receptor using site directedmutagenesis: Importance of glutamate 106. Neuropharmacology 1997; 36: 637-47.
10. Hazai E, Joshi P, Skoviak EC, Suryanarayanan A, Schulte MK, Bikadi Z. A comprehensive study on the 5-hydroxytryptamine3A receptor binding of agonists serotoninand m-chlorophenylbiguanidine. Bioorg Med Chem 2009; 17: 5796-805.
11. Price KL, Lummis SCR. The role of tyrosine residues in theextracellular domain of the 5-hydroxytryptamine3 receptor. JBiol Chem 2004; 279: 23294-301.
12. 3A receptor. Biochemistry 2009; 48: 9278-86.
13. Steward LJ, Boess FG, Steele JA, Liu D, Wong N, Martin IL. Importance of phenylalanine 107 in agonist recognition bythe 5-hydroxytryptamine3 (A) receptor. Mol Pharmacol 2000; 57: 1249-55.
14. 3 receptorbinding site using modeling and radioligand binding. J Biol Chem 2005; 280: 20476-82.
15. 3 receptor. J Biol Chem 1999; 274: 5537-41.
16. 3 receptor - the relationship between structure and function. Neuropharmacology 2009; 56: 273-84.
17. 3 receptor as atherapeutic target. Expert Opin Ther Targets 2007; 11: 527-40.
18. 3 receptor:heterogeneity in distribution and function among species. Mol Pharmacol 1995; 48: 407-16.
19. 3B subunit isa major determinant of serotonin-receptor function. Nature 1999; 397: 359-63.
20. 3B receptorsubunit. J Biol Chem 1999; 274: 30799-810.
21. 3E receptor subunits: evolution, distribution and function. J Neurochem 2009; 108: 384-96.
22. 3 receptors. Proc Natl Acad Sci USA 2005; 102: 12595-600.
23. 2+-permeable ionchannels. Proc Natl Acad Sci USA 1998; 95: 11456-61.
24. (3A) receptorisoforms. Naunyn-Schmiedeberg's Arch Pharmacol 2000; 362: 392-401.
25. 3 receptors. Trends Pharmacol Sci 2008; 29: 437-44.
26. Tzvetkov MV, Meineke C, Oetjen E, Hirsch-Ernst K, Brockmöller J. Tissue-specific alternative promoters of theserotonin receptor gene HTR3B in human brain andintestine. Gene 2007; 386: 52-62.
27. 3 receptor in CNSdisorders. Neurochem Res 1998; 23: 653-9.
28. 3 receptor subtype inthe rat brain and spinal cord. J Comp Neurol 1998; 402: 385-401.
29. 3 receptor mRNA. Proc Natl Acad Sci USA 1993; 90: 1430-4.
30. 3H]zacopride as radioligands. Synapse 1992; 10: 271-81.
31. 3 receptors in mammalianhindbrain. Trends Pharmacol Sci 1990; 11: 135-7.
32. 3H] ICS 205-930. Neuroscience 1989; 31: 393-400.
33. 7 receptor expression and function in thecircular muscle of the human colon. Life Sci 2007; 80: 1198-205.
34. Chetty N, Coupar IM, Tan YY, Desmond PV, Irving HR. Distribution of serotonin receptors and interacting proteins inthe human sigmoid colon. Neurogastroenterol Motil 2009; 21: 551-8.e15.
35. 4 receptors in the human stomach and duodenum. Neurogastroenterol Motil 2007; 19: 342-8.
36. 3 receptors. Gastroenterology 2005; 128: 1317-26.
37. 3 receptors in the rat gastrointestinal tract. Gastroentrology 2002; 123: 217-26.
38. 3 receptorsin the rat and mouse intestinal tract: a comparative study. Brit J Pharmacol 2006; 148: 1012-21.
39. 3 receptor mediatingcontraction of rat isolated jejunum. Eur J Pharmacol 1996; 312: 215-25.
40. 3 agonist MKC-733 on the rat, mouse and guinea-pig digestivetract. Pharmacology 2008; 81: 104-9.
41. Wouters MM, Farrugia G, Schemann M. 5-HT receptors oninterstitial cells of Cajal, smooth muscle and enteric nerves. Neurogastroenterol Motil 2007; 19: 5-12.
42. Yamano M, Ito H, Miyata K. Species differences in the 5-hydroxytryptamine-induced contraction in the isolated distalileum. Jpn J Pharmacol 1997; 74: 267-74.
43. Fu L-W, Longhurst JC. Reflex pressor response to arterialphyenylbiguanide: role of abdominal sympathetic visceralafferents. Am J Physiol Heart Circ Physiol 1998; 275: H2025-H35.
44. 3 receptor. J Biol Chem 2008; 283: 6826-31.
45. 3 receptors native to neuroblastoma cells. Neuropharmacology 2003; 44: 214-23.
46. 3AB receptor. Proc Natl Acad Sci USA 2008; 105: 722-7.
47. Niesler B, Weiss B, Fischer C, et al. Serotonin receptor gene HTR3A variants in schizophrenic and bipolar affectivepatients. Pharmacogenetics 2001; 11: 21-7.
48. 3 receptor mutations identified in schizophrenicpatients. J Mol Neurosci 2006; 30: 273-81.
49. 3A receptor. Pharmacogenetics 2004; 14: 165-72.
50. Navari RM. Pharmacological management of chemotherapyinducednausea and vomiting focus on recent developments. Drugs 2009; 69: 515-33.
51. Roila F, Warr D, Clark-Snow RA, et al. Delayed emesis:moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 104-8.
52. Latreille J, Pater J, Johnston D, et al. Use of dexamethasoneand granisetron in the control of delayed emesis for patientswho receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 1174-8.
53. Navari RM, Madajewicz S, Anderson N, et al. Oralondansetron for the control of cisplatin-induced delayedemesis: a large, multicenter, double-blind, randomizedcomparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13: 2408-16.
54. 3 receptorantagonist antiemetics: is there cause for concern? Oncol 2002; 7: 65-72.
55. 3 antagonists for the preventionof chemotherapy-induced nausea and vomiting: acomparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173-89.
56. Geling O, Eichler H-G. Should 5-hydroxytryptamine-3receptor antagonists be administered beyond 24 hours afterchemotherapy to prevent delayed emesis? Systematic reevaluationof clinical evidence and drug cost implications. JClin Oncol 2005; 23: 1289-94.
57. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetronimproves prevention of chemotherapy-induced nausea andvomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase III trial comparingsingle doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-7.
58. 3 receptor antagonist results of a phase III, singledosetrial versus dolasetron. Cancer 2003; 98: 2473-82.
59. 3 receptor antagonists and antiemesis. In: 5-Hydroxytryptamine-3 receptor antagonists; King FD, Jons BJ, Sanger GJ, Eds. Boca Raton (FL): CRC Press 1994: pp. 255-317.
60. Tremblay P-B, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of theefficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003; 21: 2147-55.
61. Tanaka M, Kobayashi D, Murakami Y, et al. Geneticpolymorphisms in the 5-hydroxytryptamine type 3B receptorgene and paroxetine-induced nausea. Int JNeuropsychopharmacol 2008; 11: 261-7.
62. Meineke C, Tzvetkov MV, Bokelmann K, et al. Functionalcharacterization of a -100_-102delAAG deletion-insertionpolymorphism in the promoter region of the HTR3B gene. Pharmacogenet Genomics 2008; 18: 219-230.
63. Fasching PA, Kollmannsberger B, Strissel PL, et al. Polymorphisms in the novel serotonin receptor subunit geneHTR3C show different risks for acute chemotherapy-inducedvomiting after anthracycline chemotherapy. J Cancer Res Clin Oncol 2008; 134: 1079-86.
64. 3 receptor antagonist antiemeticefficacy. Pharmacogenomics 2008; 9: 1027-33.
65. Longstreth G, Thompson W, Chey W, Houghton L, Mearin F, Spiller R. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
66. Spiller R. Recent advances in understanding the role ofserotonin in gastrointestinal motility in functional boweldisorders: Alterations in 5-HT signalling and metabolism inhuman disease. Neurogastroenterol Motil 2007; 19: 25-31.
67. 4 receptors of the release of 5-hydroxytryptamine fromthe guinea-pig small intestine. Naunyn-Schmiedeberg's Arch Pharmacol 1993; 347: 137-40.
68. Schwörer H, Ramadori G. Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human smallintestine in vitro. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 357: 548-52.
69. Mertz HR. Irritable bowel syndrome. N Engl J Med 2003; 349: 2136-46.
70. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4, and 7 receptors. Neurogastroentenol Motil 2005; 17: 637-42.
71. Camilleri M, Von Der Ohe M. Drugs affecting serotoninreceptors. Baillière's Clin Gastroent 1994; 8: 301-19.
72. Costedio M, Hyman N, Mawe G. Serotonin and its role incolonic function and in gastrointestinal disorders. Dis Colon Rectum 2007; 50: 376-88.
73. Crowell DM. Role of serotonin in the pathophysiology of theirritable bowel syndrome. Br J Pharmacol 2004; 141: 1285-93.
74. Kapeller J, Houghton LA, Mönnikes H, et al. First evidencefor an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene withdiarrhea predominant irritable bowel syndrome. Hum Mol Genet 2008; 17: 2967-77.
75. Sachar EJ, Baron M. The biology of affective disorders. Ann Rev Neurosci 1979; 2: 505-17.
76. Niesler B, Flohr T, Nöthen MM, et al. Association betweenthe 5'-UTR variant C 178T of the the serotonin receptor geneHTR3A and bipolar affective disorder. Pharmacogenetics 2001; 11: 471-5.
77. Iidaka T, Ozaki N, Matsumoto A, et al. A variant C 178T in theregulatory region of the serotonin receptor gene HTR3Amodulates neural activation in the human amygdala. JNeurosci 2005; 25: 6460-6.
78. Melke J, Westberg L, Nilsson S, et al. A polymorphism in theserotonin 3A (HTR3A) gene and its association with harmavoidance in women. Arch Gen Psychol 2003; 60: 1017-23.
79. Mizuta N, Akiyoshi J, Sato A, et al. Serotonin receptor 3A(HTR3A) gene is associated with personality traits, but notpanic disorder. Psychol Gen 2008; 18: 44.
80. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonintype 2A, 3A and 3B receptor and the seotonin transportergenes on paroxetine and fluvoxamine efficiacy and adversedrug reactions in depressed Japanese patients. Neuropschyhobiology 2006; 53: 186-95.
81. Yamada K, Hattori E, Iwayama Y, et al. Distinguishablehaplotype blocks in the HTR3A and HTR3B region in the Japanese reveal evidence of association of HTR3B withfemale major depression. Biol Psychol 2006; 60: 192-201.
82. Frank B, Niesler B, Nothen MM, et al. Investigation of thehuman serotonin receptor gene HTR3B in bipolar affectiveand schizophrenic patients. Am J Med Genetics B Neuropsychol Genet 2004; 131B: 1-5.
83. Gatt JM, Williams LM, Schofield PR, et al. Impact of the HTR3A gene with early life trauma on emotional brainnetworks and depressed mood. Depress Anxiety 2010; 27: 752-9
84. Gatt JM, Nemeroff CB, Schofield PR, et al. Early life stresscombined with serotonin 3A receptor and brain-derivedneurotrophic factor valine 66 to methionine genotypesimpacts emotional brain and arousal correlates of risk fordepression. Biol Psychol 2010; 68: 818-24.
85. 3 A receptors varies with receptor density anddesensitization. Mol Pharmacol 2008; 73: 314-22.
86. Bambico FR, Gobbi G. The cannabinoid CB1 receptor andthe endocannabinoid anandamide: possible antidepressanttargets. Expert Opin Ther Targets 2008; 12: 1347-66.
87. 3)receptor. Mol Psychol 2003; 8: 994-1007.
88. Craddock N, Lendon C. Chromosome workshop:Chromosomes 11, 14, and 15. Am J Med Genetics B Neuropsychol Genet 1999; 88: 244-54.
89. Meltzer HY. Clozapine: Is another view valid? Am J Psychol 1995; 152: 821-5.
90. 3 receptors inthe cerebral cortex and superior cervical ganglion of the rat. Eur J Pharmacol 1990; 182: 465-72.
91. 3 receptor. Biochem Biophys Res Commun 1996; 225: 957-60.
92. Ji X, Takahashi N, Branko A, et al. An association betweenserotonin receptor 3B gene (HTR3B) and treatment-resistantschizophrenia (TRS) in a Japanese population. Nagoya JMed Sci 2008; 70: 11-7.
93. Gu B, Wang L, Zhang A-P, et al. Association between apolymorphism of the HTR3A gene and therapeutic responseto risperidone treatment in drug-naive Chinese schizophreniapatients. Pharmacogenet Genomics 2008; 18: 721-7.
94. Ji X, Takahashi M, Saito S, et al. Relationship between threeserotonin receptor subtypes (HTR3A, HTR2A and HTR4)and treatment-resistant schizohrenia in the Japanesepopulation. Neurosci Lett 2008; 435: 95-8.
95. 3B receptor genes not associated withclozapine response. Schizophr Res 2002; 58: 93-7.
96. Souza RR, De Luca V, Meltzer HY, Lieberman JA, Kennedy JL. Influence of serotonin 3A and 3B receptor genes onclozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010; 20: 274-6.
97. Blanc O, Brousse G, Meary A, Leboyer M, Llorca P-M. Pharmacogenetic of response efficacy to antipsychotics inschizophrenia: pharmacodynamic aspects. Review andimplications for clinical research. Fund Clin Pharmacol 2010; 24: 139-60.
98. 3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychoticsin schizophrenia. Pharmacogenet Genomics 2009; 19: 843-51.
99. Kay SR, Fiszbein A, Opler LA. The positive and negativesyndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
100. Akhondzadeh S, Mohammadi N, Noroozian M, et al. Addedondansetron for stable schizophrenia: A double blind, placebo controlled trial. Schizophr Res 2009; 107: 206-12.
101. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidolfor chronic, treatment-resistant schizophrenia: A doubleblind, randomized, placebo-controlled study. Schizophr Res 2006; 88: 102-10.
102. 3E influencessustained attention in schizophrenia patients. Eur Neuropsychopharmacol 2010; 20: 414-20.
103. Feinberg-Zadek PL, Davies PA. Ethanol stabilizes the openstate of single 5-hydroxytryptamine(3A) (QDA) receptors. JPharmacol Exp Therap 2010; 333: 896-902.
104. 3 receptor-channels in NCB-20 neuroblastoma cells. Neuropharmacology 2000; 39: 561-70.
105. Zhang L, Hosoi M, Fukuzawa M, Sun H, Rawlings RR, Weight FF. Distinct molecular basis for differential sensitivityof the serotonin type 3A receptor to ethanol in the absenceand presence of agonist. J Biol Chem 2002; 277: 46256-64.
106. Johnson BA, Campling GM, Griffiths P, Cowen PJ. Attenuation of some alcohol-induced mood changes and thedesire to drink by 5-HT(3) receptor blockade - a preliminarystudyin healthy male-volunteers. Psychopharmacology 1993; 112: 142-4.
107. Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K. Effect of naltrexone and ondansetron on alcohol cueinducedactivation of the ventral striatum in alcoholdependentpeople. Arch Gen Psychol 2008; 65: 466-75.
108. Kenna GA. Medications acting on the serotonergic systemfor the treatment of alcohol dependent patients. Curr Pharmaceut Des 2010; 16: 2126-35.
109. 3 receptor in depression: a probable neuronal target? JPsychopharmacol 2010; 24: 455-69.
110. Ducci F, Enoch M-A, Yuan Q, et al. HTR3B is associatedwith alcoholism with antisocial behavior and alpha EEGpower-an intermediate phenotype for alcoholism and comorbidbehaviors. Alcohol 2009; 43: 73-84.
111. 3 receptor sensitivity additively predictalcohol and drug dependence. Biol Psychol 2010; 67: 292.
112. Auranen M, Varilo T, Alen R, et al. Evidence for allelicassociation on chromosome 3q 25-27 in families with autismspectrum disorders originating from a subisolate of Finland. Mol Psychol 2003; 8: 879-84.
113. Rehnström K, Ylisaukko-oja T, Nummela I, et al. Allelicvariants in HTR3C show association with autism. Am J Med Genetics B Neuropsychiatr Genet 2009; 150B: 741-6.
114. Anderson BM, Schnetz-Boutaud NC, Bartlett J, et al. Examination of association of genes in the serotonin systemto autism. Neurogenetics 2009; 10: 209-16.
115. 3 subtype ofserotonin receptor contributes to nociceptive processing via anovel subset of myelinated and unmyelinated nociceptors. JNeurosci 2002; 22: 1010-9.
116. 3 receptorantagonist tropisetron. Scand J Rheumatol 2004; 33: 44-8.
117. 3 receptor antagonist, on fatigue inchronic hepatitis C: A randomised, double blind, placebocontrolled study. Gut 2005; 54: 1169-73.
118. 3 receptorantagonists regulate autonomic cardiac dysfunction inprimary fibromyalgia syndrome. Rheumatol Int 2007; 27: 1025-30.
119. Späth M, Stratz T, Neeck G, et al. Efficacy and tolerability ofintravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004; 33: 267-70.
120. Stratz T, Farber L, Varga B, Baumgartner C, Haus U, Müller W. Fibromyalgia treatment with intravenous tropisetronadministration. Drugs Exp Clin Res 2001; 27: 113-8.
121. 3 receptor antagonist, in thetreatment of chronic fatigue syndrome patients - A pilotstudy. Netherlands J Med 2003; 61: 285-9.
122. Stratz T, Fiebich B, Haus U, Müller W. Influence oftropisetron on the serum substance P levels in fibromyalgiapatients. Scand J Rheumatol 2004; 33: 41-3.
123. 3 receptors. Drug Dev Res 1993; 28: 87-93.
124. Feyer P, Zimmermann JS, Titlbach OJ, Buchali A, Hinkelbein M, Budach V. Radiotherapy-induced emesis. An overview. Strahlenther Onkol 1998; 174: 56-61.
125. 3 receptors. J Physiol 2002; 544: 897-912.
126. 4 ligands: an update of medicinal chemistryresearch in the last few years. Curr Med Chem 2010; 17: 334-62.
127. Sugai T, Suzuki Y, Sawamura K, Fukui N, Inoue Y, Someya T. The effect of 5-hydroxytrptamine 3A and 3B receptorgenes on nausea induced by paroxetine. Pharmacogenet J 2006; 6: 351-6.
128. 3 genes contribute to pathological phenotypes? Biochem Soc Trans 2006; 34: 872-6.
129. Windemuth A, Calhoun VD, Pearlson GD, Kocherla M, Jagannathan K, Ruaño G. Physiogenomic analysis oflocalized fMRI brain activity in schizophrenia. Ann Biomed Eng 2008; 36: 877-88.
130. Hammer C, Kapellar J, Endele M, et al. Functional variants ofthe serotonin receptor type 3A and B gene are associatedwith eating disorders. Pharmacogenet Genomics 2009; 19: 790-9.
131. Walstab J, Hammer C, Bonisch H, Rappold G, Niesler B. Naturally occurring variants in the HTR3B gene significantlyalter properties of human heteromeric 5-hydroxytrptamine-3A/B receptors. Pharmacogenet Genomics 2008; 18: 793-802.
132. Goecke TW, Ekici AB, Niesler B, et al. Two naturallyoccurring variants of the serotonin receptor gene HTR3C areassociated with nausea in pregnancy. Acta Obstet Gynecol Scand 2010; 89: 7-14.